As previously mentioned, nintedanib and pirfenidone, the first two antifibrotic agents approved by the FDA for IPF, were shown to significantly reduce the rate of respiratory function decline acting on numerous inflammatory targets, including the TGFβ pathway [82,83,104]. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.